Tonix Pharmaceuticals (TNXP) announced the publication of a paper entitled, “A CXCR4 Partial Agonist, Improves Immunotherapy by Targeting Immunosuppressive Neutrophils and Cancer-Driven Granulopoiesis,” in the peer-reviewed journal Cancer Cell, that represents a collaboration between scientists at Tonix and Columbia University’s Medical School and presents data demonstrating that treatment with murine TNX-1700 increased survival and decreased metastases in animal models of gastric cancer. Combination treatment of mTNX-1700 with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone. mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes
- Tonix Pharma Presents Data at Rheumatology Congress
- Tonix Pharmaceuticals presented data, analyses of TNX-102 SL treatment effects
- Tonix Pharma Appoints James Hunter to Board
- Tonix Pharmaceuticals appoints Hunter to board of directors